Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 09, 2017 06:30 ET | Source: Epizyme, Inc.

Epizyme President of Research and Chief Scientific Officer, Robert Copeland, Announces Retirement from the Company

CAMBRIDGE, Mass., March 09, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that President of...
February 27, 2017 09:06 ET | Source: Epizyme, Inc.

Epizyme Announces 2016 Fourth Quarter and Full-Year Results Conference Call Date and March Investor Conferences

CAMBRIDGE, Mass., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will...
February 07, 2017 06:30 ET | Source: Epizyme, Inc.

Epizyme Elects Kevin Conroy to its Board of Directors

CAMBRIDGE, Mass., Feb. 07, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that the Company has...
February 02, 2017 06:30 ET | Source: Epizyme, Inc.

Epizyme to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., Feb. 02, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that the Company will...
January 03, 2017 06:30 ET | Source: Epizyme, Inc.

Epizyme Announces Presentation at J.P. Morgan 35th Annual Healthcare Conference

CAMBRIDGE, Mass., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that Robert Bazemore,...
November 28, 2016 06:30 ET | Source: Epizyme, Inc.

Epizyme Announces Fast Track Designation for Tazemetostat in DLBCL and Provides Solid Tumor Program Update

FDA Grants Tazemetostat Fast Track Designation for DLBCL with EZH2 Activating Mutations Company Focuses Phase 2 Solid Tumor Study on INI1-Negative Tumors and Expands Epithelioid Sarcoma Cohort ...
November 21, 2016 11:00 ET | Source: Epizyme, Inc.

Epizyme President of Research and Chief Scientific Officer Named AAAS Fellow

CAMBRIDGE, Mass., Nov. 21, 2016 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that President of...
November 03, 2016 06:30 ET | Source: Epizyme, Inc.

Epizyme Provides Update on Execution of Clinical Program and Reports Third Quarter 2016 Financial Results

Robust Clinical Program Underway for Tazemetostat in Multiple Cancer Indications and Treatment Settings as Both Monotherapy and Combination Agent Conference Call to Be Held Today at 8:30 a.m....
October 31, 2016 06:30 ET | Source: Epizyme, Inc.

Epizyme Expands Clinical Programs through Cooperative Research and Development Agreements with the National Cancer Institute

CAMBRIDGE, Mass., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that it has entered...
October 27, 2016 06:30 ET | Source: Epizyme, Inc.

Epizyme to Report Business Highlights and Third Quarter 2016 Financial Results on November 3, 2016

CAMBRIDGE, Mass., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management...